** Shares of Sinopharm Group 1099.HK rise 4.1% to HK$18.14, the biggest intraday pct gain since October 7
** Stock hits the highest point since April 23, snapping three straight session of losses, and is top pct gainer in the Hang Seng Index .HSI, which climbs 0.2%
** The Chinese pharmaceutical, healthcare products and medical devices distributor said its first-quarter net profit up 2.6% y/y at 1.46 billion yuan ($200.11 million) while revenue down 3.8% y/y at 141.7 billion yuan
** Citi keeps "buy" rating given Sinopharm's earnings growth potential from expectations of industry consolidation down the road, likely market share gain due to network expansion and less concern on finance costs
** Hang Seng Commerce & Industry Index .HSNC slips 0.2%, healthcare index .HSCIH falls 1.5%** Stock down 14.9% YTD
($1 = 7.2961 Chinese yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。